Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Weibo Corp (WB) Price & Performance

Novo Nordisk A/STrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Weibo Corp — how do they compare? Novo Nordisk A/S trades at $46.19 (market cap $207.85B), while Weibo Corp trades at $7.75 (market cap $1.93B). The key difference: Novo Nordisk A/S is far larger — about 107.7× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.

NVOWB
Market Cap
$207.85B$1.93B
Sector
HealthMedia
52-Week High
$63.98$12.83
52-Week Low
$35.29$7.20
Enterprise Value
$222.55B$1.20B
Dividend Yield
3.81%7.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Weibo Corp

Weibo (WB) trades at $7.74, down 3.01% in the last session, with a bearish technical signal and recent earnings misses. The stock shows strong fundamentals with a low P/E of 5.5 and robust net income margin of 21.15%, while cash flow trends improved in 2025. Recent news highlights Q2 2026 results anticipation and AI developments, but competitive pressures persist.

The outlook is mixed; valuation metrics suggest undervaluation with analyst support, but earnings volatility and market sentiment risks require caution. Opportunities lie in cash flow strength and balance sheet health, while risks include user engagement challenges and macroeconomic headwinds in the social media sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB